

NIDA CTN ED Research Meeting



Betty Tai, Ph.D.
Kristen Huntley, Ph.D.
Center for the Clinical Trials Network

November 15, 2021



Celebrating 20 Years of
Research-Practice Partnerships

NIDA Clinical Trials Network

Appalachian Node

University of Pittsburgh
West Virginia University

Big South/West Node

UT Southwestern Medical Center
UT Health Science Center at San Antonio
University of California, Los Angeles

Clinical Coordinating Center

The Emmes Corporation

Data & Statistics Center

The Emmes Corporation

Florida Node Alliance

University of Miami
Columbia University

Great Lakes Node

Rush University

Greater Intermountain Node

University of Utah

Greater Southern California Node

University of California, Los Angeles

Health Systems Node

Kaiser Foundation Hospitals

New England Consortium

Yale University
McLean Hospital

New York Node

New York University
New York State Psychiatric Institute

Northeast Node

Dartmouth College

Northstar Node

Hennepin Healthcare Research Institute

Ohio Valley Node

University of Cincinnati

Pacific Northwest Node

University of Washington
Washington State University

Southwest Node


University of New Mexico

Southern Consortium Node

Medical University of South Carolina

Western States Node

Oregon Health & Science University
Stanford University



NIDA CTN ED Research Topics Summary

- Implementation of ED initiated buprenorphine programs
- Effectiveness of XR buprenorphine
- Impact of peer recovery specialist support
- Observational research on safety of higher buprenorphine dosing
- Data Science/improving capacity for ED EHR research
- Survey and EHR analysis of COVID-19 impact on patients with OUD

CCTN Scientific Officers: Udi Ghitza, Kristen Huntley, David Liu, Yanping Liu



NIDA CTN ED Studies

5 Projects & 4 Numbered Ancillary Studies:

CTN 0069: Opioid Use Disorder in the Emergency Department (ED HEALTH).

0069-A1: Retrospective Hi Dose/Low Dose

0069-A2: COVID Supplement

CTN 0079: Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder (ED-CONNECT)

0079-A1: Emergency Department Outcomes for Patients with Opioid Use Disorder (Project ACT) (HEAL)

CTN 0081: (ASPE/PCORTF funded) Emergency Medicine Opioid Data Infrastructure: Key Venue to Address Opioid Morbidity and Mortality (Project CODE PRO – Capturing Opioid Use Disorder Electronically and Patient Reported Outcomes)

CTN 0099: (HEAL) ED-INNOVATION - Pragmatic Randomized Clinical Trial - Hybrid Implementation-Effectiveness Design - comparing XR-BUP and SL BUP in 2000 patients

CTN 0099-A1: COVID EHR Analysis

CTN 0107: (HEAL) Peer Recovery Support: A Bridge to Treatment for Overdose Survivors



Highlighted NIDA ED Studies

UG3DA047003-03: EMBED: Pragmatic Trial of User-Centered Clinical Decision Support to Implement Emergency Department-Initiated Buprenorphine for Opioid Use Disorder (Melnick)

UG3DA050173-02: Optimized Interventions to Prevent Opioid Use Disorder Among Adolescents and Young Adults in the Emergency Department (Walton)

R01DA048009-01A1S1: Predicting medical consequences of novel fentanyl analog overdose using the Toxicology Investigators Consortium (TOXIC) (Manini)

R34DA045712-03: Harnessing Social Media to Reduce Cannabis Use Among Adolescents and Emerging Adults in an Urban Emergency Department (Bonar)

1R33DA049265-02: Measuring Improvement in the Quality of ED-Initiated Treatment for OUD Using Observation (McCormack)

R33DA045850-04: Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention (McGuire)

R33DA045774-03: Recovery Initiation and Management after OD (RIMO) Experiment (Scott)

R21DA048086-02: Paramedic-Administered Buprenorphine as a Bridge to Medication-Assisted Treatment (Waller)

R21DA049859-02: Effectiveness of Bridge Clinic Following Emergency Department-Initiated intervention for OUD (Mackey)



ED-Initiated Buprenorphine Resources



**NIDA Website Resources:
Initiating Buprenorphine
Treatment in the Emergency
Department**

**ACEP E-QUAL Network
Opioid Initiative**

Reducing Opioid-Associated Harm
through safer prescribing and the implementation
of evidence-based interventions



**The Yale School
of Medicine**

ED-Initiated Buprenorphine

The Yale Department of Emergency Medicine has prepared this website as a comprehensive resource for any provider seeking information on ED-initiated buprenorphine. Please check back often as we will be continuously updating the resource provided here.

KEY DOCUMENTS OF INTEREST

- Emergency Department Initiation of Buprenorphine Treatment
- Emergency Department Initiation of Buprenorphine Treatment
- Emergency Department Initiation of Buprenorphine Treatment

RESEARCH OBJECTIVES

ONLY FOCUS ON ED VISITS WHO QUALIFY FOR MEDICATION TREATMENT

OVERVIEW

Assessment & Tools

Treatment, Supervision, Adherence & DV

Discharge and Treatment Referral



National Drug Abuse Treatment

Dissemination Initiative

Clinical Trials Network

DIGITAL TRANSFORMATION

Quality Driven Emergency Care

CEDR
E-QUAL
QUALITY MEASURES

DATA ANALYTICS PLATFORM
HEALTH INFORMATION TECHNOLOGY

CA BRIDGE

TREATMENT STARTS HERE

ED X-Waiver

Training Corps.

INTERACTIVE CME LEARNING EXPERIENCE

Buprenorphine Initiation for Opioid Use Disorders in Emergency Departments

Understand...
the clinical management of opioid use disorders, buprenorphine treatment indications, and referral to ongoing treatment

Apply...
evidence-based strategies to use in the ED to improve outcomes for patients with a variety of clinical presentations

Obtain...
continuing medical education credit hours for completion of training

Discover...
evidence-based approaches for optimizing the effectiveness of care

TO ACCESS VISIT:
<https://www.drugabuse.gov/meds-and-conditions/meds-and-conditions/buprenorphine-treatment>

Quality Improvement Organizations

Sharing Knowledge. Improving Health Care.

CENTERS FOR MEDICARE & MEDICAID SERVICES

Progress is a Process

- Resources for clinicians and health systems are available and momentum in the EM community to implement MOUD programs
- XR formulations and increasing access to care in communities & via telehealth
- COVID-19
- Limited information about patient attitudes toward MOUD and how to engage patients in the ED
- Low naloxone distribution rates
- Gaps in knowledge about best practices, protocols
- Need for greater implementation and adoption



Goals of Meeting

- Highlight promising research and practices
- Describe current uptake and status of efforts to implement ED-initiated buprenorphine programs
- Facilitate connections, share information
- Identify additional research, dissemination, and implementation efforts needed for large scale-up of evidence-based practices

